Regeneron's small interfering RNA (siRNA) therapeutic cemdisiran demonstrated robust efficacy in a Phase III trial for generalized myasthenia gravis, significantly reducing complement factor 5 levels and improving clinical symptoms measured by MG-ADL scores. The monotherapy showed promise as a standalone option, with regulatory filing planned for early 2026. This advancement bolsters Regeneron's portfolio in neuromuscular diseases, marking progress in rare autoimmune conditions.